# Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]

> **NCT03480932** · PHASE2,PHASE3 · COMPLETED · sponsor: **Johns Hopkins Bloomberg School of Public Health** · enrollment: 150 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** Daclatasvir
- **DRUG:** Pegylated Interferon alfa-2a

## Key facts

- **NCT ID:** NCT03480932
- **Lead sponsor:** Johns Hopkins Bloomberg School of Public Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-02
- **Primary completion:** 2018-11-02
- **Final completion:** 2018-11-02
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2021-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03480932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03480932, "Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03480932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*